media - FDA OKs sixth gadolinium-based MRI contrast agent (also known as Gadavist/Gadovist)

Gadavist, known as Gadovist

FDA alert: Gadolinium-based Contrast Agents: Class Labeling Change - Risk of Nephrogenic Systemic Fibrosis

RECOMMENDATION: Healthcare professionals should screen patients prior to administration of a GBCA to identify those with acute kidney injury or chronic, severe, kidney disease. See the Drug Safety Communication for the complete list of recommendations to healthcare professionals and patients.